Leflunomide/hydroxychloroquine combination therapy targets type I IFN-associated proteins in patients with Sjögren’s syndrome that show potential to predict and monitor clinical response

Leflunomide/hydroxychloroquine combination therapy targets type I IFN-associated proteins in patients with Sjögren’s syndrome that show potential to predict and monitor clinical response

Objectives To assess to what extent leflunomide (LEF) and hydroxychloroquine (HCQ) therapy in patients with primary Sjögren’s syndrome (RepurpSS-I) targets type I IFN-associated responses and to study the potential of several interferon associated RNA-based and protein-based biomarkers to predict an...

Full description

Bibliographic Details
Main Authors: Cornelis P J Bekker, Maarten R Hillen, Sofie L M Blokland, Aike A Kruize, Joel AG van Roon, Timothy RDJ Radstake, Cornelia G van Helden-Meeuwsen, Marjan A Versnel, Helen L Leavis, Safae Hamkour, Ana P Lopes, Eefje HM van der Heijden
Format: Article
Language:English
Published: BMJ Publishing Group 2023-08-01
Series:RMD Open
Online Access:https://rmdopen.bmj.com/content/9/3/e002979.full

Internet

https://rmdopen.bmj.com/content/9/3/e002979.full

Similar Items